Using an ovarian cancer intra-peritoneal xenograft model, omental implants were shown to express higher levels of intra-tumoral Bclxl compared to ovarian tumors and metastatic implants in liver and mesentery [54]. Here, BCL2L1 is linked to ovarian cancer.